The once-weekly human GLP-1 analogue semaglutide provides significant reductions in HbA1c and body weight in patients with type 2 diabetes

被引：0
|
作者：
Nauck, M. A. [1 ]
Petrie, J. R. [2 ]
Sesti, G. [3 ]
Mannucci, E. [4 ]
Courreges, J-P [5 ]
Atkin, S. [6 ]
Duering, M. [7 ]
Jensen, C. B. [7 ]
Heller, S. [8 ]
机构：
[1] Ctr Diabet, Bad Lauterberg Im Harz, Germany
[2] Univ Glasgow, Glasgow G12 8QQ, Lanark, Scotland
[3] Magna Graecia Univ Catanzaro, Catanzaro, Italy
[4] Careggi Teaching Hosp, Florence, Italy
[5] Gen Hosp, Narbonne, France
[6] Hull York Med Sch, Kingston Upon Hull, N Humberside, England
[7] Novo Nordisk, Soborg, Denmark
[8] Univ Sheffield, Sheffield S10 2TN, S Yorkshire, England
来源：
DIABETOLOGIA | 2012年 / 55卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2
引用
收藏
页码：S7 / S7
页数：1
相关论文
共 50 条
  • [1] Semaglutide: The Newest Once-Weekly GLP-1 RA for Type 2 Diabetes
    Tuchscherer, Rhianna M.
    Thompson, Angela M.
    Trujillo, Jennifer M.
    ANNALS OF PHARMACOTHERAPY, 2018, 52 (12) : 1224 - 1232
  • [2] Taspoglutide, a once-weekly human GLP-1 analog, as monotherapy significantly lowers HbA1c and body weight in patients with type 2 diabetes: results from the T-emerge 1 phase 3 trial
    Raz, I.
    Fonseca, V. A.
    Kipnes, M. S.
    Durrwell, L.
    Hoekstra, J.
    Boldrin, M.
    Balena, R.
    DIABETOLOGIA, 2010, 53
  • [3] Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide
    Lau, Jesper
    Bloch, Paw
    Schaffer, Lauge
    Pettersson, Ingrid
    Spetzler, Jane
    Kofoed, Jacob
    Madsen, Kjeld
    Knudsen, Lotte Bjerre
    McGuire, James
    Steensgaard, Dorte Bjerre
    Strauss, Holger Martin
    Gram, Dorte X.
    Knudsen, Sanne Moller
    Nielsen, Flemming Seier
    Thygesen, Peter
    Reedtz-Runge, Steffen
    Kruse, Thomas
    JOURNAL OF MEDICINAL CHEMISTRY, 2015, 58 (18) : 7370 - 7380
  • [4] Liraglutide, a human GLP-1 analogue, substantially reduces HbA1c in subjects with type 2 diabetes, irrespective of HbA1c at baseline
    Vaag, A.
    Nauck, M. A.
    Brandle, M.
    Colagiuri, S.
    Schmitz, O.
    Zdravkovic, M.
    Hermansen, K.
    Garber, A.
    Zinman, B.
    DIABETOLOGIA, 2008, 51 : S68 - S69
  • [5] Influence on HbA1c and weight by baseline body mass index with once-weekly dulaglutide in Chinese patients with type 2 diabetes mellitus
    Shi, Yongquan
    Zhang, Bin
    Wu, Haiya
    DIABETES-METABOLISM RESEARCH AND REVIEWS, 2019, 35
  • [6] Levels of circulating semaglutide determine reductions in HbA1c and body weight in people with type 2 diabetes
    Overgaard, V. Rune
    Hertz, L. Christin
    Ingwersen, H. Steen
    Navarria, Andrea
    Drucker, J. Daniel
    CELL REPORTS MEDICINE, 2021, 2 (09)
  • [7] Impact of Once-Weekly Semaglutide on eGFR and Hemoglobin A1c (HbA1c) among Patients with Type 2 Diabetes and CKD: An Observational Study
    Amamoo, James J.
    Sheth, Sunny T.
    Brady, Brenna L.
    Tran, Anh Thu
    Xie Lin
    Noone, Josh
    Mehanna, Sherif
    Bakris, George L.
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2024, 35 (10):
  • [8] Once-Weekly Semaglutide Reduces HbA1c and Body Weight in Patients with Type 2 Diabetes Regardless of Background Common OAD: a Subgroup Analysis from SUSTAIN 2–4 and 10
    Matthew Capehorn
    Yasmin Ghani
    Charlotte Hindsberger
    Pierre Johansen
    Esteban Jódar
    Diabetes Therapy, 2020, 11 : 1061 - 1075
  • [9] Taspoglutide: A Once-Weekly Human GLP-1 Analogue with Improved Stability and Potency
    Sebokova, Elena
    Christ, Andreas D.
    Wang, Haiyan
    Sewing, Sabine
    Dong, Jesse Z.
    Taylor, John
    Cawthorne, Michael A.
    Culler, Michael D.
    DIABETES, 2009, 58 : A160 - A160
  • [10] Liraglutide, a human GLP-1 analogue, lowers HbA1c independent of weight loss
    Schmidt, W. E.
    Gough, S.
    Madsbad, S.
    Zinman, B.
    Falahati, A.
    Toft, A. D.
    Sesti, G.
    DIABETOLOGIA, 2009, 52 : S289 - S289
12345